Pepti Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 9/10
Best for: bloodwork inside the $99/month rather than billed on top
Pepti's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
In the price
Coaching
Not stated
No insurance needed · Vetted by our editors
One flat charge holds regardless of dose: $99 a month for injectable semaglutide, $199 for tirzepatide, each figure covering shipping, refill management, baseline labs, physician review and the drug itself. Registered in Delaware, the platform reaches 36 states with doctor-prescribed compounded peptides and GLP-1s, and its catalog passes 120 products spanning skin, cognitive, recovery, TRT and hormone, and weight-loss categories, bloodwork at home included. Insurance is not billed. Pepti prescribes nothing itself; it is the platform.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Pepti
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Pepti at a glance
- Type
- GLP-1 telehealth provider
- Starting price
- $99/mo (All-in monthly subscription covering medication, physician care, labs and shipping. A one-time non-subscription vial...)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping · Labs
- Availability
- 36 states
- FDA status
- No FDA warning letter on record
How Pepti scores
Six columns, each one computed from something Pepti has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
9.7/10$99/month is 48% below the register median of $189 for compounded semaglutide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
8.5/10does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
7.8/10Publishes coverage in 36 of 50 states.
Support10%
8.5/10The price covers medication, consult, shipping, labs.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Pepti
Last checked August 2026- Re-read the price on file across 4 dose or plan tiers
- Checked state coverage: 36 states
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with Pepti involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Pepti publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Pepti does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping, labs.
- Cheapest standing monthly prices on record: semaglutide $99, tirzepatide $199. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 36 of 50 states.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
GLP-1 medications Pepti offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Peptides Pepti offers
Pepti sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
All-in monthly subscription covering medication, physician care, labs and shipping. A one-time non-subscription vial is $124.
All-in monthly subscription. A one-time non-subscription vial is $249.
Oral semaglutide, priced above the injectable.
Oral tirzepatide, priced above the injectable.
Check the price yourself before you pay
Every figure here was read off Pepti's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping, labs
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Coverage is published for 36 states only, so this may not reach you
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Pepti charges
Pepti lists $99/month, flat regardless of dose. That sits at the affordable end of what we track. Flat dose pricing matters more than it reads: on a tiered plan the bill grows as the dose does, which means the figure that persuaded you to sign up is not the figure you end up living with.
- Compounded semaglutide — $99/month
- Compounded tirzepatide — $199/month
- Compounded semaglutide — $249/month
- Compounded tirzepatide — $399/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so Pepti is genuinely under the middle rather than merely advertising that it is.
TRYM Health dispenses semaglutide and tirzepatide from $96/month, which makes it the honest comparison to run before committing here.
What Pepti dispenses
Pepti prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
What we could verify
On the record: it operates in 36 states. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
Our read
Pepti competes on price and does it without an obvious sacrifice elsewhere: $99/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
Pepti's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay Pepti
Starting at $99/month. Check today's price, then book the free consultation.
Where Pepti is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
- If you need the FDA-approved pen rather than a compounded vial, consider Found.
- If you want a human checking in, not just a prescription, consider Oak.
- If your state is outside the area this one covers, consider Direct Meds.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Pepti review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Pepti's current pricing
Plans start at $99/month. The free consultation is where you learn whether you qualify, and what it costs today.